Pradžia › Antsvoris › Alabama › Birmingham
Antsvoris klinikiniai tyrimai Birmingham, AL
16 tyrimai dėl Antsvoris ieško dalyvių vietose Birmingham ir aplinkui (apytiksliai 30 mylių spinduliu). Atidarykite tyrimą, kad pamatytumėte, kas gali dalyvauti ir kaip susisiekti su tyrimo komanda.
Oficialus tyrimo tekstas (anglų kalba)
Ieškote dalyvių tyrimui? Pateikite jį šio puslapio viršuje – $99 už 30 dienų →
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Renkami dalyviai3 fazė
- Univ of Alabama Birmingham, Birmingham
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
Renkami dalyviai2 fazė
- University of Alabama - Birmingham, Birmingham
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
Renkami dalyviai3 fazė
- Univ of Alabama Birmingham, Birmingham
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Renkami dalyviai3 fazė
- Central Research Associates, Birmingham
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Renkami dalyviai3 fazė
- Birmingham Clinical Research, Birmingham
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Renkami dalyviai3 fazė
- Birmingham Clinical Research, Birmingham
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Renkami dalyviai3 fazė
- AURORA-1 Clinical Site, Birmingham
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Renkami dalyviai3 fazė
- AURORA-2 Clinical Site, Birmingham
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Renkami dalyviai3 fazė
- Alabama Clinical Therapeutics, Birmingham
- University of Alabama at Birmingham, Birmingham
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Renkami dalyviai3 fazėLaukiami sveiki savanoriai
- ACCOMPLISH-2 Research Site, Birmingham
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
Renkami dalyviai3 fazė
- Uni of Alabama at Birmingham, Birmingham
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
Renkami dalyviai3 fazė
- Kailera Clinical Site, Birmingham
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Renkami dalyviai3 fazė
- ACCOMPLISH-1 Research Site, Birmingham
- ACCOMPLISH-1 Research Site, Birmingham
Time-restricted Eating for Postpartum Weight Loss
Renkami dalyviai
- University of Alabama at Birmingham, Birmingham
Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
Renkami dalyviai
- University of Alabama at Birmingham, Birmingham
FELLAShip to Better Health
Renkami dalyviai
- The Worship Center Cristian Church, Birmingham
Antsvoris tyrimai kituose miestuose
- San Antonio, TX34 tyrimai
- Houston, TX33 tyrimai
- Chicago, IL28 tyrimai
- Orlando, FL27 tyrimai
- Las Vegas, NV23 tyrimai
- Miami, FL23 tyrimai
- Atlanta, GA20 tyrimai
- Dallas, TX20 tyrimai
- New York City, NY19 tyrimai
- Jacksonville, FL19 tyrimai
- Washington, DC19 tyrimai
- Austin, TX18 tyrimai
Kiti tyrimai Birmingham
- Vėžys (visų tipų)30 tyrimai
- Krūties vėžys24 tyrimai
- Nutukimas23 tyrimai
- Kiaušidžių vėžys23 tyrimai
- Nedidelinių ląstelių plaučių vėžys22 tyrimai
- Ūmi mieloidinė leukemija21 tyrimas
- Kartotinė mieloma18 tyrimai
- LOPSL17 tyrimai
- Širdies ir kraujagyslių ligos17 tyrimai
- Endometrio vėžys16 tyrimai
- 2 tipo cukrinis diabetas16 tyrimai
- Cistinė fibrozė16 tyrimai
Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.